Neuroblastoma in patients over 12 years old: a 20-year experience at the Istituto Nazionale Tumori of Milan

Marta Giorgia Podda¹, Roberto Luksch¹, Daniela Polastri¹, Lorenza Gandola², Luigi Piva³, Paola Collini⁴, Graziella Cefalo¹, Monica Terenziani¹, Andrea Ferrari¹, Michela Casanova¹, Filippo Spreafico¹, Cristina Meazza¹, Maria Rita Castellani², Serena Catania¹, Elisabetta Schiavello¹, Alfonso Marchianò², and Maura Massimino¹

¹Department of Paediatric Oncology, ²Department of Radiology and Radiotherapy, ³Department of Surgery, and ⁴Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

ABSTRACT

Aims and background. Neuroblastoma is the most common solid extracranial tumor in children. The median age of onset is 2 years, with more than 95% of patients younger than 10 years at diagnosis. As neuroblastoma is rare in adolescents and exceedingly rare in adults, few series are reported in the literature. In the present study, we analyzed the outcomes and clinical characteristics of a mono-institutional series.

Methods. We describe 27 consecutive patients over 12 years of age (range, 12-69) with previously untreated neuroblastoma treated at our Institution between 1982 and 2001.

Results. Overall survival at 5 and 10 years was 40% and 20%, respectively, and progression-free survival at 5 and 10 years was 18%. In the present series, there was a long interval between the onset of signs/symptoms and diagnosis, and between recurrence/progression and death. None had MYCN amplification.

Conclusions. The passive course of the disease in most of our patients did not reflect a more favorable outcome compared with younger patients, thus suggesting a possible genetically different subset of neuroblastoma in older patients. Free full text available at www.tumorionline.it

> Key words: adolescents, adults, ganglioneuroblastoma, neuroblastoma.

> Acknowledgments: This work was partially supported by the Associazione Bianca Garavaglia, for help and support in the field of infantile tumors, Busto Arsizio (VA), Italy.

> *Correspondence to:* Marta Giorgia Podda, MD, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Tel +39-02-2390-2588; fax +39-02-2390-2648; e-mail marta.podda@istitutotumori.mi.it

Received October 20, 2008; accepted April 8, 2010.